Massmutual Trust Co. FSB ADV Has $228,000 Holdings in Bristol-Myers Squibb Co (BMY)

Massmutual Trust Co. FSB ADV reduced its position in Bristol-Myers Squibb Co (NYSE:BMY) by 9.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,386 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Bristol-Myers Squibb were worth $228,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Legal & General Group Plc grew its holdings in shares of Bristol-Myers Squibb by 5.9% during the fourth quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock valued at $445,300,000 after buying an additional 474,820 shares during the last quarter. Phocas Financial Corp. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $73,000. Trust Co. of Virginia VA grew its holdings in shares of Bristol-Myers Squibb by 105.7% during the fourth quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock valued at $2,601,000 after buying an additional 25,712 shares during the last quarter. CSat Investment Advisory L.P. lifted its position in Bristol-Myers Squibb by 13.6% during the fourth quarter. CSat Investment Advisory L.P. now owns 2,135 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 255 shares during the period. Finally, Chescapmanager LLC lifted its position in Bristol-Myers Squibb by 22.1% during the fourth quarter. Chescapmanager LLC now owns 361,755 shares of the biopharmaceutical company’s stock valued at $18,804,000 after purchasing an additional 65,367 shares during the period. 74.28% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on BMY. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. BMO Capital Markets boosted their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research report on Wednesday. Credit Suisse Group restated a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Finally, Bank of America decreased their target price on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $59.20.

Shares of Bristol-Myers Squibb stock opened at $45.80 on Thursday. The stock has a market capitalization of $75.03 billion, a price-to-earnings ratio of 11.51, a PEG ratio of 2.39 and a beta of 0.79. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The business had revenue of $5.97 billion during the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.68 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.58%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2019/04/18/massmutual-trust-co-fsb-adv-has-228000-holdings-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: How does inflation affect different investments?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.